Welspun Corp Q2 FY27: Consol PAT +12% YoY to ₹495 Cr on Margin Gains, Revenue +6%
PAT +11.63% YoY · revenue +6.18% · margins expanding · beat vs street
₹4,643.72 Cr
+6.18% YoY
₹495.09 Cr
+11.63% YoY
10.54%
+0.5pp YoY
₹18.91
Welspun Corp's consolidated PAT rose 11.6% YoY to ₹495.09 Cr (owners' share ₹498.56 Cr) on revenue of ₹4,643.72 Cr, up 6.2% YoY — a print that tracks almost exactly with the company's own board-meeting framing of "PAT +12% YoY on margin gains; revenue up 6%." Against our pre-result preview (Q2 revenue ~₹5,000 Cr, EBITDA ₹700-750 Cr, PAT ₹250-350 Cr), revenue came in roughly 7% light, but EBITDA (~₹802 Cr, 17.28% OPM) and PAT both beat the top of the expected range comfortably — profitability, not topline, is the story this quarter.
Q2 FY-2027 vs prior quarters
Margin expansion was the real driver: operating EBITDA margin rose to 17.28% from 16.05% a year ago, and net margin to 10.66% from 10.14%, helped by a better cost-of-materials ratio (62.7% of revenue vs 63.3% YoY) even as depreciation (+54% YoY, capex-led) and other expenses rose sharply on a widened consolidation base (WCPGL stake increased to 73.9%, Sintex entities, new JVs). Sequentially PAT looks down 52.7% QoQ (₹495.09 Cr vs ₹1,047.88 Cr), but that comparison is misleading: Q1 FY27 PAT included a ₹547.93 Cr one-off gain on the sale of EPIC shares; stripped of that, Q1's adjusted PAT was ~₹499.95 Cr, making Q2 essentially flat QoQ on a like-for-like basis, with OPM easing from Q1's 19.73%.
The stock went into the print at ₹2,529, down 7.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
FY27 revenue target ₹20,000 Cr maintained (not increased). EBITDA target ₹2,850 Cr on track. Capex for KSA and US projects to be completed by FY27 year-end, full impact in FY28. FY29 early-stage discussions ongoing, no orders booked yet.
— This quarter: met
The standalone (parent-only) print tells a weaker story — PAT fell to ₹141.83 Cr from ₹365.75 Cr a year ago, but that prior-year quarter carried a ₹163.49 Cr exceptional gain; even adjusting for it, standalone PBT fell from ₹281.82 Cr to ₹186.00 Cr. This >3% divergence from the consolidated growth story reflects that subsidiary and JV contributions (Sintex, US/KSA pipe units, the EPIC associate) are now driving group profitability more than the parent entity alone. At the segment level, Steel held PBT near flat (₹571.64 Cr vs ₹552.81 Cr YoY) while the Others (plastics, including Sintex) segment's operating loss widened to ₹43.51 Cr from ₹28.29 Cr, a growing drag management will need to address.
W1
Can OPM hold near 17%+ as H2 volumes ramp, given it already eased from Q1's (one-off-inflated) 19.73% to 17.28%?
W2
FY27 guidance (₹20,000 Cr revenue / ₹2,850 Cr EBITDA) implies ~₹11,275 Cr of H2 revenue vs ₹8,725 Cr in H1 — watch Q3/Q4 execution on the record order book and new US/Jordan capacity (US expansion due March 2028, full P&L impact from FY28).
W3
Others/plastics segment loss widened to ₹43.51 Cr this quarter — watch whether Sintex-related units narrow losses or keep dragging consolidated margins.
Clean typed statement, both schedules extracted; consol PBT bridges via PBT-before-JV (613.67) + share of JV/associate profit (41.91), no exceptional-items line used at consol level in any period. Consol Q1 FY27 PAT included a one-off ₹547.93 Cr gain on sale of EPIC shares (Note 4) not present in Q2 FY27 or Q2 FY26, so YoY is clean but QoQ is distorted. Standalone Q2 FY26 included a ₹163.49 Cr exceptional gain (NSPL stake sale), inflating that base. NCI took -₹3.47 Cr of Q2 FY27 consol PAT (owners' share ₹498.56 Cr).
Informational and educational content only. Not investment advice.